

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**PATENT APPLICATION**

Inventor(s): Andrew Saxon, et al.

Application No.: 10/000,439

Filed: October 24, 2001

Title: Fusion Molecules and Methods for Treatment of
Immune Diseases

Confirmation No.: 9201

Art Unit: 1644

Examiner: Phuong N. Huynh

Customer No. 25213

INFORMATION DISCLOSURE STATEMENT**UNDER 37 C.F.R. §1.97**

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. or is identified, with an asterisk (*), as having been previously cited in priority U.S. **Patent Application No.: 09/847,208, filed: May 1, 2001,** pursuant to 37 C.F.R. §1.97-1.98.

1.98(d) A copy of any patent, publication or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge any fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 39754-0674A).

Respectfully submitted,

HELLER EHRMAN LLP

Dated: July 5, 2007

By: Leslie Mooi

Reg. No.: 37,047

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: 1.650.324.7000
Facsimile: 1.650.324.0638
Customer No.: 25213

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
	39754-0674A	10/000,439
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 10/24/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
*American Autoimmune Related Diseases Association, Questions and Answers, pp. 1-4, 07/26/2001 (http://www.aarda.org/questions_and_answers.html)		
*Resources for Health Professionals: Anaphylaxis, pp. 1-10, 09/18/2001 (http://www.worldallergy.org/professional/allergy_update/anap.../anaphylaxisynopsis.shtm)		
*ANSARI, AA, et al., "Epitope Mapping of the Branched Chain Alpha-Ketoacid Dehydrogenase Dihydrolipoyl Transacylase (BCKD-E2) Protein that Reacts with Sera from Patients with Idiopathic Dilated Cardiomyopathy", (abstract), J Immunol, 153(10):4754-65, 15 November 1994		
*AroTec Diagnostics Limited - B2-Glycoprotein 1 (human), pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5002.htm)		
*AroTec Diagnostics Limited - Myeloperoxidase (pANCA) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5009.htm)		
*AroTec Diagnostics Limited - Proteinase 3 (cANCA) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5008.htm)		
*AroTec Diagnostics Limited - La (SSB) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5010.htm)		
*AroTec Diagnostics Limited - Ro (SSA) Antigen, pp. 1-3, July 11, 2001 (http://webnz.com/arotec/masa5011.htm)		
*AroTec Diagnostics Limited - Sm Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5007.htm)		
*AroTec Diagnostics Limited - RNP/Sm Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5006.htm)		
*AroTec Diagnostics Limited - Scl-70 Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5001.htm)		
*AroTec Diagnostics Limited - Parietal Cell Antigen (H/K-ATPase), pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5004.htm)		
*AroTec Diagnostics Limited - Jo-1 Antigen, pp. 1-2, 07/11/2001 (http://webnz.com/arotec/masa5005.htm)		
**"Autoantigen Sequences", pp. 1-3, 07/11/2001 (http://129.206.51.31/mb/ana_base.html)		
**"Autoimmune Disease: Rapid Progress in our Understanding of Immune Function Promises More Effective Treatments for Autoimmune Disorders", Nature Biotechnology, Vol. 18, pp. IT7-IT9, Supplement 2000		
*BARKER RN, et al., "Red Blood Cell Glycophorins as B and T-cell Antigens in Canine Autoimmune Haemolytic Anaemia", (abstract) Vet Immunol Immunopathol, 47(3-4):225-38, August 1995		
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0674A	SERIAL NO. 10/000,439
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 10/24/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	**"alpha β -Crystallin In Multiple Sclerosis", J. Immunol, Vol. 129-135, pp. 1-5, July 20, 2001 (http://www.albany.net/~tjc/crystalline.html)	
	*BAJRAMOVIC, JJ, et al., "Presentation of $\alpha\beta$ -Crystallin to T Cells in Active Multiple Sclerosis Lesions: An Early Event Following Inflammatory Demyelination", The American Association of Immunologists, Vol 164, pp. 4359-4366, 2000	
	*BIGAZZI, PE, MD, Lecture on "Autoimmune Disease", The University of Connecticut, pp. 1-6, July 30, 2001, (http://155.37.1.60/Lectures/PB/Autoimmune.html)	
	*BONFA, E., et al., "Frequency and Epitope Recognition of Anti-Ribosome P Antibodies from Humans with Systemic Lupus Erythematosus and MRL/lpr Mice are Similar", (abstract), J Immunol; 140(1):3434-3437, 15 May 1998	
	*BRIDGES, SL, Jr., et al., "T-Cell Receptor Peptide Vaccination in the Treatment of Rheumatoid Arthritis", Emerging Therapies for Rheumatoid Arthritis, Vol. 24, pp. 641-650, 1998	
	*CAMBIER, JC, "Commentary: Inhibitory receptors abound?", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 5993-5995, 1997	
	*CHAPMAN, MARTIN D., et al., "Recombinant Allergens for Diagnosis and Therapy of Allergic Disease", J Allergy Clin Immunol, pp. 409-418, 2000	
	*CRITCHFIELD, JM, et al., "T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis", Science Feb 25; 263(5150): 1139-43, 1994 (abstract)	
	*DE PALMA, R, et al., "Use Of Altered Peptide Ligands To Modulate Immune Responses As A Possible Immunotherapy For Allergies", Allergy: 55: Suppl 61: 56-59, 2000	
	*DECKER, PATRICE, et al., "Inhibition Of Caspase-3-Mediated Poly (ADP-Ribose) Polymerase (PARP) Apoptotic Cleavage By Human PARP Autoantibodies And Effect On Cells Undergoing Apoptosis", The Journal Of Biological Chemistry, © 2000 by The American Society For Biochemistry And Molecular Biology, Inc., Vol. 275, No. 12, pp. 9043-9046, 24 March 2000	
	*DIETERICH, W., et al., Identification Of Tissue Transglutaminase As The Autoantigen Of Celiac Disease", Nat Med; 3(7):797-801, July 1997 (abstract)	
	*Merck Corp., "Disorders With Type III Hypersensitivity Reactions", The Merck Manual, Sec. 12, Ch. 148, Hypersensitivity Disorders, July 12, 2001	
	*DITZEL, HENRIK J., "Human Antibodies In Cancer And Autoimmune Disease", Immunologic Research; 21(2-3):185-193, 2000	
	*EARNSHAW WC, et al., "Identification Of A Family Of Human Centromere Proteins Using Autoimmune Sera From Patients With Scleroderma", (abstract) Chromosoma, 91(3-4):313-321, 1985	
	*ELKON, KB, et al., "Lupus Autoantibodies Target Ribosomal P Proteins", (abstract) J Exp Med, 162(2): 459-471, August 1 1985	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0674A	SERIAL NO. 10/000,439
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 10/24/2001	GROUP: 1644
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	*FABIEN N., et al., "Autoantibodies Directed Against The Ribosomal P Proteins Are Not Only Directed Against A Common Epitope Of The P0, P1 And P2 Proteins", (abstract) J Autoimmune, 13(1): 103-110, August 1999	
	*FARIA AM, et al., "Oral Tolerance: Mechanisms And Therapeutic Applications", (abstract), Adv Immunol, 73:153-264, 1999	
	*FRAMPTON, G., et al., "Identification Of Candidate Endothelial Cell Autoantigens In Systemic Lupus Erythematosus Using A Molecular Cloning Strategy: A Role For Ribosomal P Protein P0 As An Endothelial Cell Autoantigen", Rheumatology (Oxford), (abstract) 39(10):1114-1120, October 2000	
	*GIOVANNONI, G, et al., "Multiple Sclerosis And Its Treatment", (abstract) J R Coll Physicians Lond, 33(4):315-22, Jul-Aug 1999	
	*GOLD, DANIEL P., et al., "T-Cell Receptor Peptides As Immunotherapy For Autoimmune Disease", Critical Reviews™ In Immunology, (abstract) 17:507-510, 1997	
	*GOLD, DP, "Results Of A Phase I Clinical Trial Of A T-Cell Receptor Vaccine In Patients With Multiple Sclerosis. II. Comparative Analysis Of TCR Utilization In CSF T-Cell Populations Before And After Vaccination With A TCRV Beta 6 CDR2 Peptide", (abstract) J Neuroimmunol, 76(1-2):29-38, July 1997	
	*GOLD, HA, et al., "The RNA Processing Enzyme RNase MRP Is Identical to the Th RNP And Related to RNase P", (abstract) Science, 245(4924):1377-80, 22 September 1989	
	*GOTTLIEB, A.B., et al., Anti-CD4 Monoclonal Antibody Treatment of Moderate to Severe Psoriasis Vulgaris: Results of a Pilot, Multicenter, Multiple-Dose, Placebo-Controlled Study", (abstract) J Am Acad Dermatol, 43(4):595-604, October 2000	
	*GUNNARSSON, ANDREAS, et al., "Molecular Properties Of The Goodpasture Epitope", The Journal Of Biological Chemistry, Vol. 275, No. 40, pp. 30844-30848, 6 October 2000	
	*HASELDEN, B.M., et al., "Peptide-Mediated Immune Responses in Specific Immunotherapy", Int Arch Allergy Immunol, 122(4):229-37, 2000	
	*HELLMARK, T., et al., "Characterization of Anti-GBM Antibodies Involved in Goodpasture's Syndrome", (abstract) Kidney Int, 46(3):823-9, September 1994	
	*HIRANO, T., et al., "Human Tissue Distribution of TA02, which is Homologous with a New Type of Aspartic Proteinase, Napsin A", (abstract) Jpn J Cancer Res, 91(10):1015-21, October 2000	
	*"Histones and Subclasses", July 30, 2001, Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0019.htm)	
	*HUGHES, G.R., "The Antiphospholipid Syndrome: Ten Years On", (abstract) Lancet, 342(8867):341-344, August 7, 1993	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0674A	SERIAL NO. 10/000,439
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 10/24/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	*KARLSSON, F.A., et al., "Major Parietal Cell Antigen in Autoimmune Gastritis with Pernicious Anemia is the acid-producing H ⁺ , K ⁺ adenosine Triphosphatase of the Stomach", (Abstract) J Clin Invest, 81(2):475-9, February 1988	
	*KOZLOWSKI, MAYA, et al., "SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain", Molecular and Cellular Biology, pp. 2089-2099, Vol. 18, No. 4, April 1998	
	*Kronus, "Addison's Disease", Enzyme Steroid 21-Hydroxylase (21-OH) Antibody, (http://www.kronus.com/products/addisons.html), July 30, 2001	
	*Kronus, "Celiac Disease", Tissue Transglutaminase (tTg) Autoantibody, (http://www.kronus.com/products/celiac.html), July 30, 2001	
	*Kronus, "Diabetes", (http://www.kronus.com/products/diabetes.html), July 30, 2001	
	*Kronus, "Neuromuscular", Myasthenia Gravis, (http://www.kronus.com/products/neuromuscular.html), July 30, 2001	
	*Kronus, "Thyroid Autoimmune", (http://www.kronus.com/products/thyroid-auto.html), July 30, 2001	
	*KROGSGAARD, M., et al., "Visualization of Myelin Basic Protein (MBP) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (HLA)-DR2-MBP 85-99 complex", (abstract), J Exp Med, April 17;191(8):1395-412, 2000	
	*LACHE, MARK, "Specific Immunotherapy", British Medical Bulletin, 56 (No. 4): 1019-1036, 2000	
	*MALBEC, ODILE, et al., "The SH2 Domain-containing Inositol 5-Phosphatase SHIP1 Mediates Cell Cycle Arrest by FcγRIIB", JBC Papers in Press., pp. 1-29, May 18, 2001	
	*MCNEIL, H. PATRICK, et al., "Anti-Phospholipid Antibodies are Directed Against a Complex Antigen that Includes a Lipid-Binding Inhibitor of Coagulation: β ₂ -Glycoprotein I (apolipoprotein H)", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 4120-4124, Medical Sciences, June 1990	
	*MIMORI, T., et al., "Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from Patients with Rheumatic Disorders", (abstract) J. Biol. Chem., 261(5):2274-8, February 15, 1986	
	*MISAKI, Y., et al., "The 56K Autoantigen is Identical to Human Annexin XI", (Abstract) J. Biol. Chem., 269(6):4240-6, 11 February 1994	
	*Immunovision (Brochure), "Mitochondrial Antigen", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0020.htm), July 30, 2001	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0674A	SERIAL NO. 10/000,439
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 10/24/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	*MU, F.T., et al., "EEA1, an Early Endosome-Associated Protein. EEA1 is a Conserved Alpha-Helical Peripheral Membrane Protein Flanked by Cysteine "Fingers" and Contains a Calmodulin-Binding IQ Motif", J. Biol. Chem., 270(22):13503-11, June 2 1995	
	*Immunovision (Brochure), "nRNP", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0020.htm)	
	*NAKAJIMA, ATSUKO, et al., "Antigen-Specific T Cell-Mediated Gene Therapy in Collagen-Induced Arthritis", The Journal of Clinical Investigation, Vol. 107, No. 10, pp. 1293-1301 May 2001	
	*NEWKIRK, MARIANNA M., et al., "Autoimmune Response to U1 Small Nuclear Ribonucleoprotein (U1 snRNP) Associated with Cytomegalovirus Infection", Arthritis Res, 3: 253-258, July 30 2001	
	*NORMAN, PHILIP S., "Therapeutic Potential of Peptides in Allergic Disease", Annals of Allergy, Vol. 71, pp. 330-333, September 1993	
	*OKANO, Y., et al., "Autoantibody to Th Ribonucleoprotein (Nucleolar 7-2 RNA Protein Particle) in Patients with Systemic Sclerosis", Arthritis Rheum, 33(12):1822-8, December 1990, (abstract)	
	*ONO, S.J., "Molecular Genetics of Allergic Diseases", Annu Rev Immunol, 18:347-66, 2000, (abstract)	
	*ROCK, KENNETH L., et al., "Degradation of Cell Proteins and the Generation of MHC Class I-Presented Peptides", Annu. Rev. Immunol., 17:739-79, 1999, (abstract)	
	*CASCIO P, et al., " 26Sproteasomes and Immunoproteasomes Produce Mainly N-Extended Cersions of an Antigenic Peptide", EMBO J, 20(10):2357-2366, May 15, 2001, (abstract)	
	*SERWOLD T, et al., "ER Aminopeptidases Generate a Unique Pool of Peptides for MHC Class I Molecules", Nat. Immunol., July 2001, (abstract)	
	*YEWEDELL, JW., et al., "Not Such a Dismal Science: The Economics of Protein Sythesis, Folding, Degradation and Antigen Processing", Trends Cell Biol, 11(7):294-297, July 2001, (abstract)	
	*FIEBIGER E., et al., "Cytokines Regulate Proteolysis in Major Histocompatibility complex Class II-Dependent Antigen Presentationby Dendritic Cells" J. Exp. Med., 193(8):881-892, April 16, 2001, (abstract)	
	*STOLTZE L, et al., "Two New Proteases in the MHC Class I Processing Pathway", Nat. Immunol., 1(5):413-418, November 2000, (abstract)	
	*MUNO D., et al., "Generation of both MHC Class I- and Class II-Restricted Antigenic Peptides from Exogenously Added Ovalbumin in Murin Phagosomes", FEBS Lett, 478(1-2):178-182, July 28, 2000, (abstract)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0674A	SERIAL NO. 10/000,439
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 10/24/2001	GROUP: 1644
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	*MANOURY B., et al., "An Asparaginyl Endopeptidase Processes a Microbial Antigen for Class II MHC Presentation", Nature, 396(6712):625-627, December 17, 1998, (abstract)	
	*Auto Immune, Inc., "Overview of Oral tolerance Therapy" Research and Development - OT Technology, July 30, 2001, (http://www.autoimmuneinc.com/R_D/tech.html)	
	*Immunovision (Brochure), "PCNA Antigen", Purified Antigens for Autoimmune Testing, July 30, 2001, (http://www.immunovision.com/pg0061.htm)	
	*PISETSKY, D.S., "The Role of Bacterial DNA in Autoantibody Induction", (abstract) Curr Top Microbiol Immunol, 247:143-155, 2000	
	*RICKERT, M., et al., "Fusion Proteins for Combined Analysis of Autoantibodies to the 65-kda Isoform of Glutamic Acid Decarboxylase and Islet Antigen-2 in Insulin-Dependent Diabetes Mellitus", Clin Chem, 47(5):926-34, May 2001, (abstract)	
	*Immunovision (Brochure), "Ribosomal P Antigen", Purified Antigens for Autoimmune Testing, July 30, 2001, (http://www.immunovision.com/pg0021.htm)	
	*RIDER, LISA G., et al., "Laboratory Evaluation of the Inflammatory Myopathies", Clinical and Diagnostic Laboratory Immunology, Vol. 2, No. 1, p. 1-9, Jan. 1995	
	*RIESE, RICHARD J., et al., "Cathepsin S Activity Regulates Antigen Presentation And Immunity", J. Clin. Invest., Vol. 101, No. 11, 2351-2363, June 1998	
	*Immunovision (Brochure), "Ro/SS-A Antigen", July 30, 2001, (http://www.immunovision.com/pg0013.htm)	
	*NOEL ROSE, et al., The Autoimmune Diseases: Table of Contents, Third Edition, Academic Press 1998	
	*SARIC, TOMO, et al., "MHC Class I-Presented Antigenic Peptides are Degraded in Cytosolic Extracts Primarily by Thimet Oligopeptidase", JBC Papers in Press., Published July 30, 2001	
	*Immunovision (Brochure), "Sc1-70 Antigen", Purified Antigens for Autoimmune Testing" (http://www.immunovision.com/pg0017.htm), July 30, 2001	
	*Immunovision (Brochure), "SMITH (sm) Antigen", Purified Antigens for Autoimmune Testing" (http://www.immunovision.com/pg0015.htm), July 30, 2001	
	*SELA, M., "Specific Vaccines Against Autoimmune Diseases", C R Acad Sci III; 322(11):933-8, November 1999, (abstract)	
	*SCHUPPAN, D, et al., "Identification of the Autoantigen of Celiac Disease", Ann N Y Acad Sci., 859:121-6, 17 November 1998, (abstract)	
	*STEINMAN, L., "Multiple Sclerosis: a Coordinated Immunological Attack Against Myelin in the Central Nervous System", Cell, 85(3):299-302, May 3 1996, (abstract)	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0674A	SERIAL NO. 10/000,439
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 10/24/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	*STEINMAN, L., et al., "Prospects for Specific Immunotherapy in Myasthenia Gravis" FASEB J., 4(10):2726-31, July 1990, (abstract)	
	*STENMARK, HARALD, et al., "Endosomal Localization of the Autoantigen EEA1 is Mediated by a Zinc-Binding FYVE Finger", The Journal of Biological Chemistry, Vol. 271, No. 39, pp. 24048-24054, September 27 1996	
	*Tan EM, "Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology", (abstract), Adv Immunol 1989, 44:93-151	
	*TARGOFF IN, "Autoantibodies to Aminoacyl-Transfer RNA Synthetases for Isoleucine and Glycine. Two Additional Synthetases are Antigenic in Myositis; J Immunol, 144(5):1737-1743, 1 March 1990, (abstract)	
	*National Institute of Allergy and Infectious Diseases, "Understanding Autoimmune Disease - What are some Examples of Autoimmune Diseases: Rheumatoid Arthritis. (http://www.niaid.nih.gov/publications/autoimmune/examples.htm), July 11, 2001	
	*VAN SECHEL, ARIANNE C., et al., "EBV-Induced Expression and HLA-DR-Restricted Presentation by Human B Cells of aB-Crystallin, a Candidate Autoantigen in Multiple Sclerosis", The American Association of Immunologists, 1999	
	*VAN VENROOIJ, W.J., et al., "Manual of Biological Markers of Disease", Table of Contents, Kluwer Academic Publishers,	
	*VAN VENROOIJ, W.J., Venroij Research Team, Research Topics, General Introduction, "Autoantigens", (abstract), Department of Biochemistry, University of Nijmegen, 11 July 2001	
	*WALLNER, BARBARA P., Short Analytical Review, "Peptide Therapy for Treatment of Allergic Diseases, Clinical Immunology and Immunopathology, Vol. 80, No. 2, August, pp. 105-109, 1996	
	*WARDROP, III, R.M., et al, "Oral Tolerance in the Treatment of Inflammatory Autoimmune Disease, Inflamm. res., 48, pp. 106-119, 1990	
	*YAMAMOTO, A.M., et al., "Anti-Titin Antibodies in Myasthenia Gravis: Tight Association with Thymoma of Nonthymoma Patients", Archives of Neurology, Vol 58, No.6, June 2001	
	*GERMAIN, R.N., "The T Cell Receptor for Antigen: Signaling and Ligand Discrimination", The Journal of Biological Chemistry, Vol. 276, No. 38, pp. 35223-35226, July 2, 2001	
	*Immunovision (Brochure), "La/SS-B", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0014.htm), July 30, 2001	
	*ROSE, N.R., "The Autoimmune Diseases: A Discussion of the Causes and Treatment of Autoimmune Diseases", American Autoimmune Related Diseases Associate, July 26, 2001	
	ZHU, DAOCHENG, "A Chimeric Human-Cat Fusion Protein Blocks Cat-Induced Allergy", Nature Medicine, pp. 1-4, March 2005 (published online at http://www.nature.com/naturemedicine)	
EXAMINER		DATE CONSIDERED